FEATURED NEWS

• AAOA Launches Pharmacy Toolkit to Increase Pharmacist-Patient Engagement Around Safe Use, Storage and Disposal of Opioids

  September 18, 2018

  Allied Against Opioid Abuse (AAOA), a national initiative to help prevent prescription opioid abuse and misuse through education, has created a pharmacy toolkit (http://bit.ly/2xiNmnj) to equip pharmacists with resources to engage and educate patients about the safe use, storage and disposal of pain medicines.

• HDA Statement on Senate Passage of Legislation to Address Opioid Abuse Epidemic

  September 17, 2018

  Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the Senate passage of comprehensive opioid legislation, the SUPPORT for Patients and Communities Act (H.R. 6).

• HDA Statement on Introduction of House Legislation to Support Enhanced Data Sharing Between DEA, Supply Chain Partners

  September 14, 2018

  Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the introduction of the Using Data to Prevent Opioid Diversion Act of 2018 (H.R. 6779) by Rep. Ken Buck (R-Colo.)

• HDA Traceability Seminar to Bring Together Pharmaceutical Supply Chain Professionals to Assess DSCSA Progress

  September 12, 2018

  The Healthcare Distribution Alliance (HDA) will convene pharmaceutical supply chain industry leaders at its Traceability Seminar, October 17–19 in Washington, D.C. The 2018 seminar will educate attendees about where the pharmaceutical supply chain is in relation to achieving full implementation of the Drug Supply Chain Security Act (DSCSA) in 2023; what to expect in the future as the industry approaches the final deadline; and available resources, tools and guidance on a range of traceability topics.

• HDA Research Foundation Report Analyzes Reverse Distribution of Pharmaceutical Products

  August 6, 2018

  A new report published by the HDA Research Foundation entitled The Role of Reverse Distribution provides insights into the reverse distribution of pharmaceutical products. The Foundation estimates that this channel accounts for 3.5 to 4 percent of all pharmaceutical sales — more than 120 million product units — and exceeds $13 billion in product value.